Reports Q1 revenue $3.7M, consensus $4.7M. “Our commitment to advancing a prostate cancer franchise is demonstrated by our continued progress with JANX007, clinical initiation of JANX014, and advancement of JANX013 toward the clinic,” said David Campbell, Ph.D., President and CEO of Janux. “Our ongoing clinical study with JANX011 has been designed to support our emerging autoimmune disease opportunity.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JANX:
- Janux Therapeutics price target lowered to $24 from $29 at BofA
- Janux Therapeutics Adjusts Board Class Structure for Director
- Janux Therapeutics price target lowered to $28 from $50 at JonesResearch
- Janux Therapeutics announces discontinuation of JANX008 clinical development
- Janux’s JANX011 First‑in‑Human Study: Early Safety Readout Could Shape Autoimmune Upside